Angiogenesis in gastric cancer: hitting the target?
Mené sur 355 patients atteints d'un adénocarcinome avancé de l'estomac ou de la jonction gastro-œsophagienne, cet essai international de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité du ramucirumab, un anticorps monoclonal antagoniste de VEGFR-2, en traitement de deuxième ligne
Gastric cancer, a daunting global health problem, is the fourth leading cause of cancer-related mortality worldwide. Survival in gastric cancer has improved with the validation and implementation of adjuvant therapy combined with surgery, including postoperative adjuvant chemotherapy, perioperative chemotherapy, and postoperative combined chemotherapy and radiotherapy. However, little progress has been made in either the treatment of advanced gastric cancer or the development of novel targeted ...
The Lancet , commentaire, 2012